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Background: The TNM staging criteria for gastric carcinoma have seen numerous revisions, the most recent of
which are reflected in the seventh edition AJCC TNM cancer staging manual.
Methods: A retrospective evaluation of the sixth and seventh TNM classification of gastric cancer on a prospective
database, regarding patients operated on for primary gastric cancer, was conducted. The end point of the study
was prognosis evaluation in terms of overall survival.
Patients operated on for primary gastric cancer between September 2003 and March 2012 at our Department of
Emergency and General Surgery, were consecutively retrieved in this study; a total of 114 patients were considered.
Cardia gastric cancers, gastric lymphomas and gastrointestinal stromal tumors (GIST) were excluded. Median and
mean follow-up periods were 22.5 and 27.7 months (range 15 days to 5 years). Both TNM6 and TNM7 were used to
evaluate our patients. Overall survival and survival rates at different stages were analyzed using the Kaplan-Meier
method and differences were determined using a log-rank test. Cox’s proportional hazard model was used to
identify significant factors related to prognosis in a multivariate analysis.
Results: Overall survival between the sixth and seventh TNM classification was not significantly different. Both the
Kaplan-Meier analysis and the multivariate analysis showed that the major negative prognostic factor was
lymphovascular invasion (P < 0.001 in the univariate analysis and P = 0.035 to 0.048 in the multivariate analysis).
Stage distribution and stage-related survival changed from the sixth to the seventh edition, especially in T3 stage
where median survival for the sixth edition was 720 days versus 1,200 days for the seventh edition. Moreover,
differences were shown in the survival rate of N1 versus N2 stages within the seventh TNM.
Conclusions: Even though further studies are needed in order to increase the number of patients studied, the
seventh edition seems to provide a more accurate prognosis, especially regarding N1 and N2 tumors, showing that
the most important prognostic factor is lymphovascular invasion.
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Gastric tumor is a disease with one of the poorest progno-
ses, being the second cause of tumor-related mortality in
the world. Five-year overall survival (OS) is 25% or less,
especially in USA, Europe, and China [1,2]. Its incidence
varies according to different countries: Asian countries have
a high incidence of 50/100,000, whereas in the occidental
countries incidence falls to 18/100,000 [3]. For these
reasons, the staging system is continuously evolving.* Correspondence: luiginagraziosi@yahoo.it
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reproduction in any medium, provided the orThe main tumor-staging system is the AJCC/UICC TNM
classification in which three parameters are simultaneously
evaluated: gastric wall or other organ involvement by the
primitive tumor (T); lymph node involvement (N); presence
of distant metastases (M). Between the end of 2009 and
2010, a new TNM edition was developed, becoming the
seventh edition.
The major differences are: 1) lymph node involvement
staging; 2) primitive tumor staging; 3) the exclusion from
the gastric cancer staging of esophageal cancer with epicen-
ter within 5 cm of the esophagogastric junction (EGJ) that
also extends into the esophagus; 4) the exclusion of Mx and
Nx definitions from this classification (Additional file 1).l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.






















Adjuvant chemotherapy 52 466
Neo-adjuvant chemotherapy 11 96
HIPEC 15 132
Gastrectomy 46 403
Gastric resection 66 579
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tients with gastric cancer is lymph node involvement,
and it is clear that standardized dissection patterns relate
to patient survival rate [4]. This is the main reason why,
in the seventh edition, the substantial changes pertain
mainly to lymph node staging; however it does not
define the minimum number of lymph nodes necessary [5]
for optimum staging. The aim of the study was to conduct
a retrospective evaluation of the sixth and seventh TNM
classification of gastric cancer on a prospectively- collected
database. The end point of the study was prognosis
evaluation in terms of overall survival.
Methods
A database was adopted in order to store all data needed.
Data included demographic (age at diagnosis and sex),
esophagogastroduodenoscopic (EGDS) description, CT
scan description, surgical procedure (resection type and
lymphadenectomy), Lauren grade, pathological features,
post-operative outcome, pTNM6 and pTNM7 stages,
chemotherapy and hyperthermic intraperitoneal chemo-
therapy (HIPEC) treatments and serum tumor markers at
the diagnosis and follow-up.
All data were stored prospectively and survival was
updated at one, three and six months from surgery and
every six months thereafter for 10 years.
All patients were treated according to the principles of
the Helsinki Declaration, and signed an informed
consent form.
Patients operated on for primary gastric cancer
between September 2003 and March 2012 at our
Department of Emergency and General Surgery of
Perugia, were consecutively retrieved in this study.
Cardia gastric cancers, gastric lymphomas and gastrointes-
tinal stromal tumors (GIST) were excluded; a total of 114
patients were considered. Follow-up for the entire study
population was conducted until death or the cut-off date
that we arbitrarily decided (March 2012).
Median and mean follow-up periods were 22.5 and
27.7 months (range 15 days to 5 years), respectively. The
clinicopathologic features of the patients are listed in
Table 1. Of the 114 patients who underwent surgery, 11
(9.6%) had received neo-adjuvant chemotherapy, 52
(46.6%) received adjuvant chemotherapy after surgery
and 15 (13.2%) received HIPEC either as prophylactic
(pT4a and/or positive cytology) or as therapeutic
(only when peritoneal cancer index was < 6) treatment.
The intravenous chemotherapy regimen administered
included platinum chemotherapies in association with
capecitabine and docetaxel or epirubicin, whereas for
HIPEC, mitomycin in association with cisplatin were
administered.
The pT category, pN category and stage of each tumor
were classified according to both the sixth and seventheditions of the AJCC TNM staging system. Figure 1
shows the frequency distribution of examined lymph
nodes for the entire cohort of patients.
Statistical analysis
Overall survival and survival rates in different stages
according to both the sixth and seventh TNM editions,
were analyzed using the Kaplan-Meier method and
the differences were determined using a log-rank test.
In multivariate analysis, Cox’s proportional hazard
model was used to identify significant factors related
to prognosis.
A P < 0.05 was regarded as statistically significant.
Graph Pad (©2013 GraphPad Software, Inc) Prism
version 5.0 and SAS (© SAS Institute Inc.) statistical
softwares were used to generate these analyses.
Figure 1 Frequency distribution of lymph nodes.
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Comparisons of survival curves between patients in
different TNM stages according to the sixth and seventh
edition systems, are shown in Figure 2 (a-d). Additional
file 2 and Additional file 3 also show how patients were
divided into different pT, pN and stages according to
both the TNM editions. Our tables show that patients in
our database are mostly in an advanced disease stage
using either the sixth or seventh TNM classification.
The main differences between the two editions’ sub-
classification apply to patients in stage IV. As a matter
of fact, a higher number of patients fall in to stage IV
according to sixth TNM due to the fact that in theFigure 2 Survival comparison among different TNM editions in differerevised edition, stage IV patients are the only ones with
metastatic disease.
As shown, significant differences in prognosis could
not always be observed between different TNM editions;
early stages (I, II) have a higher survival, with a median
of above five years for stage I and of two years for
stage II.
On the other hand, the prognosis in higher stages
decreases significantly in both sixth and seventh
TNM. Survival curves of patients in different pT
categories, pN categories and stages, according to the
seventh TNM edition system are shown in Figure 3
(a-c respectively). As shown, significant differences in
prognosis could be observed in patients in pT2 and
pT3 categories (P < 0.001) and in pN1 and pN2
categories (P < 0.005).
Five-year OS curve, according to the pT category,
showed a significantly different survival rate among
patients in T1 and T2 and T2 and T3, meaning that
muscularis propria involvement and more specifically,
subserosa involvement, are major negative prognostic
factors.
Also the five-year survival curve according to the pN
category, showed a significant change in prognosis
between patients with one to two positive lymph
nodes (N1) and patients with three to six positive
lymph nodes (N2) (P < 0.005). Median survival was above
1,800 days and 720 days respectively.nt stages: (a) stage I, (b) stage II, (c) stage III, (d) stage IV.
Figure 3 Survival curves of patients in different pT, pN and stages in the seventh TNM.
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Figure 4 Survival curves of patients in different pT, pN and
stages in the sixth TNM.
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TNM edition, some differences occurred as shown in
Figure 4. According to the sixth TNM edition, there is
less homogeneity in the stages, and a lower five-year
survival difference in the pT and pN categories.
To further investigate the validity of our study, we
performed univariate and two-step multivariate analyses
in which Cox’s proportional hazard model was used
to identify significant factors related to prognosis
(Additional file 4). Analyzing various different factors: sex,
age, tumor location, Lauren grade, lymphovascular
invasion, adjuvant therapy, neo-adjuvant therapy, HIPEC
and TNM [6,7] staging, it is clear that the lymphovascular
invasion status significantly correlates with survival
(P < 0.001). Moreover, in the second step of multivariate
analysis, lymphovascular invasion is confirmed to be an
independent prognostic factor.
Discussion
Accurate gastric cancer staging provides the means
for appropriate treatment selection and defining
prognosis. It is also the standard for reporting
cancer incidence and outcomes. The TNM staging
criteria for gastric adenocarcinoma have seen numer-
ous revisions, the most recent of which are reflected
in the seventh edition AJCC TNM cancer staging
manual [6]. Previous sixth edition T categories T2a
and T2b (denoting muscularis proprial and subserosal
invasion, respectively) have been reclassified into T2
(muscularis proprial) and T3 (subserosal), respectively; this
change reflects a significantly longer disease-specific
five-year survival rate for tumors invading the
muscularis propria compared with those invading the
subserosa [7-9].
Upstaging from T2 to T3 places each tumor in a
higher stage grouping for all stages. The previously
categorized T3 category (serosal invasion) has now
been changed to T4a, with the classification of
adjacent structure involvement changed from T4 to
T4b. No longer do T4b tumors denote stage IV
disease by default; M1 disease is now characterized
only by the presence of distant metastases and
peritoneal washing-positive cytology. This is important
as en bloc surgical resection for T4 tumors is
considered a viable surgical strategy for potentially
curative therapy.
In our study, we demonstrated a significantly different
survival among patients in T1 and T2 according to pT
categories, meaning that muscularis proprial invasion is
a negative prognostic factor for survival. In addition, we
showed significant survival discrimination between pT2
and pT3 groups, emphasizing the concept that
subserosal involvement is a worse prognostic factor than
serosal involvement.Accordingly, we believe that the T stage categories in
the seventh AJCC edition staging system have better
prognostic value than the categories in the sixth edition.
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cases in which the number of metastatic lymph nodes
were 1 to 6, 7 to 15 and ≥ 16 were classified as N1, N2
and N3, respectively. Of these, the N3 was classified as
stage IV.
According to the seventh edition of AJCC TNM sta-
ging system which was newly revised, cases in which the
number of metastatic lymph nodes are 1 to 2, 3 to 6 and
greater than 7 are determined to be N1, N2 and N3, re-
spectively. Of these, the N3 group was sub-classified;
cases in which the number of metastatic lymph nodes
are 7 to 15 and greater than 16, are determined to be
N3a and N3b, respectively. However, because N3a and
N3b are classified as the same TNM stage, the new clas-
sification system is not relevant for this group.
As described here, some cases were defined as the
same TNM stage, although the range of number of
lymph nodes involved was too wide. Despite the same
TNM stage, the difference in the survival rate based on
a specific cut-off point might reach a statistical signifi-
cance as Kim has demonstrated in his work [10].
Although the sixth edition UICC TNM staging system is
simple, reliable, and reproducible, for cases in which < 15
lymph nodes are examined, N stage may be incorrect be-
cause of stage migration. A method for bypassing this
problem is to consider the ratio between metastatic and
examined lymph nodes. On the other hand, in the se-
venth edition system, patients may be classified as N3
as long as the number of retrieved lymph nodes is
more than seven, and thus, this revised edition system
may reduce stage migration.
We demonstrated a large survival difference between
N0 and N1 groups; as N1 denotes one to two involved
nodes, this may suggest that prognosis is different for
patients with a single metastatic node compared with
two nodes. This lymph nodal subdivision is important in
particular for patients with an early disease stage that
could benefit from perioperative chemotherapy treat-
ment to reduce postsurgical recurrences.
It also suggests that there may be subsets of N0 pa-
tients with poor prognostic features not captured by
the current staging criteria. The different prognosis
between the seventh AJCC N1 and N2 observed in
our patients may have been influenced by the greater
frequency of locally advanced gastric cancer patients
due to the lack of screening tests, and an increasing
incidence of proximal gastric cancer compared to that
in Eastern populations.
Although some reports have shown no difference in
survival rate between patients experiencing metastasis in
one to three lymph nodes compared to those with four
or more lymph nodes in early gastric cancer [11,12],
comparison of five-year survival rate of gastric cancer by
old and new UICC stage classification suggested thatmetastasis in more than four lymph nodes is a significant
risk factor for recurrence.
Nio et al. [13] reported no difference in survival rate
between stages N2 and N3 using the fifth UICC edi-
tion but did observe a significant difference in survival
rate when N1 was divided into N1a (metastasis in one
to three lymph nodes) and N1b (metastasis in four to
six lymph nodes), supporting the subdivision of N1.
The UICC/AJCC TNM classification for gastric can-
cer is a manual containing the periodical promotion
and modification about cancer staging. The seventh
UICC/AJCC pN stage of gastric cancer is the latest
edition for evaluating positive node metastases from
gastric cancer, and has been validated to be more ac-
curate than the previous edition of the pN stage for
predication of the OS of patients after surgery. Actu-
ally, the comparatively elaborate pN stages of the se-
venth UICC/AJCC TNM classification for gastric
cancer can significantly improve the prognostic precision
of patients following curative resection. In our previous
study, we demonstrated the seventh UICC/AJCC pN
stage of gastric cancer was superior to the fifth/sixth
UICC/AJCC pN stage.
We demonstrated in our multivariate analysis that the
most influential factor for the prognosis of our patients,
affected by locally advanced tumor, was lymphovascular
involvement. For this reason, an accurate and extensive
surgical lymphadenectomy with target chemotherapy
could improve prognosis.
Although our study showed that the recategorized
N staging system is more accurate than the traditional
N staging system, further prospective studies would
provide additional evidence supporting the use of a
recategorized N staging system and metastatic lymph
node ratio as a standard for the N staging of gastric
cancer, especially when the number of retrieved lymph
nodes is insufficient.
The biggest revision in the seventh AJCC edition is
the division of sixth AJCC edition stage IV gastric can-
cer into stages IIB, IIIA, IIIB, IIIC, and IV. Sixth edi-
tion stage IV cases without distant metastasis (T1-
4N3M0 or T4N1-2) are no longer classified as stage
IV in the seventh AJCC edition system. Gastric cancer
without distant metastasis has a good prognosis, so
the necessity of a more detailed categorization has been
disputed [14-18]. Using the sixth AJCC edition system, sur-
vival rates were significantly lower for T4N1-2M0 than
they were for T1-3N3M0 groups and also for any T or any
N M1 group compared to that of the T4N3M0 group.
In the present study, no significant difference was ob-
served between seventh edition stages IA and IB or be-
tween stages IIA and IIB that represent early disease
stages. In these groups there were a small number of pa-
tients. However, significant differences were observed
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and IIIC).
The five-year survival rates were 80% for the seventh
AJCC edition stage IIB and 40% for IIIA, 45% for the
seventh AJCC edition stage IIIB and 0% for IIIC, which
were more accurate prognoses than when these cases
were categorized as stage IV in the sixth AJCC classifica-
tion system and IIIA, IIIB, IIIC patients. We showed that
the seventh AJCC edition might be more useful than the
sixth edition for prognosis prediction and establishing
adjuvant therapy for stage IV gastric cancer patients.
Conclusions
Even though further studies are needed in order to increase
the number of patients studied, the seventh edition seems
to provide a more accurate prognosis, especially regarding
N1 and N2 tumors, showing that the most important
prognostic factor is lymphovascular invasion.
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